Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE CODEINE PHOSPHATE versus TRIPROLIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE CODEINE PHOSPHATE versus TRIPROLIDINE HYDROCHLORIDE.
PROMETHAZINE HYDROCHLORIDE; CODEINE PHOSPHATE vs TRIPROLIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative via blockade of central and peripheral H1 receptors and antagonism of dopamine D2 receptors. Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia and cough suppression; it also has antitussive effects via central action.
Competitive antagonist of histamine H1 receptors; inhibits histamine-mediated vasodilation, increased capillary permeability, and bronchoconstriction in allergic reactions.
Promethazine hydrochloride 6.25-25 mg / codeine phosphate 10-20 mg (based on codeine component) orally every 4-6 hours as needed. Maximum codeine dose: 60 mg per dose, 120 mg per day.
2.5 mg orally every 4-6 hours as needed; maximum 10 mg per 24 hours.
None Documented
None Documented
Promethazine: 10-19 hours (terminal); Codeine: 2.4-4 hours (terminal), prolonged in hepatic impairment. Clinical context: Dosing interval typically 4-6 hours for codeine; promethazine accumulates with repeated dosing.
Terminal elimination half-life approximately 3–4 hours in healthy adults; prolonged in renal impairment (up to 12 hours).
Promethazine: Renal (70-80% as metabolites, <1% unchanged); Codeine: Renal (70-90% as metabolites, 5-15% unchanged). Biliary/feces: Minor (<10% total).
Renal (primarily as metabolites; ~70% recovered in urine within 24 hours, <5% unchanged). Fecal elimination is minor.
Category A/B
Category A/B
Antihistamine / Antiemetic
Antihistamine